DAVID NATAN

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

TITAN PHARMACEUTICALS INC

Filing Date Source Excerpt
2023-05-19 David Natan is Chair of the Audit Committee... David Natan 2022 compensation total $23,438.
2023-11-28 Mr. Natan is a member of the Board. The shares of common stock beneficially owned include (i) 125,000 shares of common stock subject to options exercisable within 60 days of November 17, 2023 with a weighted average exercise price of $1.35 and (ii) 66,250 shares of common stock issuable pursuant to unreleased stock awards.

Data sourced from SEC filings. Last updated: 2026-02-03